Clariant Q3 EBITDA before exceptional items falls 7% to CHF 151.5 million

• Clariant’s third-quarter 2026 EBITDA before exceptional items fell 7% year over year to CHF 151.5 million.
• Sales rose 7% year over year to CHF 968.8 million.
• The earnings decline reflected normalized Corporate costs, weaker Catalysts operating leverage, and unfavorable mix and raw-material effects in Care Chemicals and Catalysts.
• Clariant maintained its 2026 EBITDA margin guidance before exceptional items of around 18%, supported by a strong fourth-quarter order book, particularly in Catalysts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clariant AG published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.